Navigation Links
Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
Date:7/26/2013

nded periods of time.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver a full year of treatment from a single minipump placement. Intarcia's robust intellectual property portfolio protects ITCA 650 through 2031.

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. In addition, delivering medicines just once or twice yearly virtually ensures patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is pursuing a Phase 3-stage development program for type 2 diabetes and has additional programs ongoing for weight regulation to control obesity. For more information on the Company, please visit www.intarcia.com.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.


'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
3. Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) ... Cava (IVC) Filters - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena ... million by 2016. The North America ... value while Europe claims approximately ...
(Date:12/15/2014)... BRIDGEWATER, N.J. , Dec. 15, 2014 ... US (EURONEXT: SAN and NYSE: SNY) are collaborating with ... Cholesterol Counts , an awareness program that will ... and the risks associated with high LDL-C (bad cholesterol). ... .com to take a brief poll and answer ...
(Date:12/15/2014)... --  DaVita HealthCare Partners Inc.  (NYSE: ... most innovative health care communities, today announced that ... Research  (DCR) and  HealthCare Partners Clinical Research , will ... research and data analytics services, specifically in patients ... disease (ESRD), as well as primary care and ...
Breaking Medicine Technology:Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4
... Incorporated (Nasdaq: VPHM ) today announced that ... of the European Medicines Agency (EMA) has adopted a ... Authorization (PUMA) for Buccolam® (midazolam, oromucosal solution), for treatment ... and adolescents, from 3 months to less than 18 ...
... serving Virginia patients reduced healthcare-acquired infection rates (HAIs) a ... of $1.2 million in additional costs to the health ... existing federal hand washing protocols, these hospitals improved patient ... patient length-of-stay and unnecessary readmissions. VHHA Services, ...
Cached Medicine Technology:ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union 2ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union 3ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union 4ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union 5Virginia Hospitals Reduce Infections 41% 2Virginia Hospitals Reduce Infections 41% 3
(Date:12/17/2014)... 17, 2014 Project Veritas is releasing ... videos of MIT economist and Obamacare architect Jonathan Gruber ... O’Keefe conducted the interview, which is being distributed on ... was intentional mislabeling in the Affordable Care Act in ... A two-hundred-and-fifty billion dollar per year tax grab. , ...
(Date:12/17/2014)... Alan Mozes HealthDay ... In the world of infectious diseases, one worrisome phenomenon is ... people. The process -- known as zoonosis -- is ... look for signs that an animal-borne disease might make inroads ... just such a development -- and the culprits in this ...
(Date:12/17/2014)... 2014 (HealthDay News) -- Poor students get more fruits and ... study finds. But, the opposite is true for students ... and vegetables at school may give a healthy boost to ... matter what the family income level, students all ate a ... found. The study was published recently in the journal ...
(Date:12/17/2014)... By Alan Mozes ... -- With the holiday party season fast approaching, a new ... and make DUI arrests have fewer drunk drivers on their ... driving laws more vigilantly are better able to deter inebriated ... "Hardly any new laws are being passed regarding drinking ...
(Date:12/17/2014)... Kathleen Doheny HealthDay Reporter ... loss is rampant in America, and work commitment is a ... No. 1 sleep killer," said Dr. Mathias Basner, an assistant ... of Pennsylvania Perelman School of Medicine. A time-use survey ... that work is the main activity exchanged for sleep. Short ...
Breaking Medicine News(10 mins):Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3
... , WEDNESDAY, Nov. 17 (HealthDay News) -- Diabetics may ... is just a cell phone screen away. Researchers ... phone monitoring system that automatically picks up patients, home ... via radio signals from monitoring equipment outfitted with Blue-tooth ...
... mysterious culprit that threatens headaches, stuffy noses, skin rash ... people worldwide drink wine. The discovery could help winemakers ... and whites with less potential to trigger allergy symptoms, ... Journal of Proteome Research . Giuseppe ...
... WEDNESDAY, Nov. 17 (HealthDay News) -- The U.S. Food and ... that their products are illegal. In warning letters to ... malt beverages is an "unsafe food additive," and the companies ... does not find support for the claim that the addition ...
... not been high on the list of targets for treating ... the development of neurodegenerative diseases than has been realized. ... the pericyte in a surprising new role as a key ... brain tissue from harmful substances. By manipulating pericyte levels, scientists ...
... News) -- Get ready, get set, quit! Thursday marks ... which urges all smokers to lay off the habit for at ... about smoking and a large decrease in smoking rates since the ... local and nationwide events meant to encourage smokers to quit for ...
... 17, 2010) HealthGrades, the nation,s leading independent ... patients a list of those hospitals with the ... receiving a donor organ. HealthGrades annual evaluation of ... clinical quality data, based on patient outcomes, for ...
Cached Medicine News:Health News:Cell Phone 'Telemonitoring' May Help Control Blood Pressure 2Health News:Cell Phone 'Telemonitoring' May Help Control Blood Pressure 3Health News:FDA Cracks Down on Caffeinated Alcohol Drinks 2Health News:FDA Cracks Down on Caffeinated Alcohol Drinks 3Health News:The pericyte becomes a player in Alzheimer's, other diseases 2Health News:The pericyte becomes a player in Alzheimer's, other diseases 3Health News:The pericyte becomes a player in Alzheimer's, other diseases 4Health News:Smokers Urged to Join Thursday's Great American Smokeout 2Health News:Nation's top hospital organ transplant centers identified by HealthGrades 2
Compression Bra...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test is ... Modified Albumin (IMA®) by measuring the cobalt ... serum sample. First identified in the early ... comes in contact with ischemic tissue in ...
... Test is a clinical chemistry assay that ... the cobalt binding capacity of albumin in ... the early 1990s, IMA is produced when ... tissue in the heart. During ischemia, the ...
Medicine Products: